Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model

被引:28
作者
Kim, MK
Zhou, W
Tessier, PR
Xuan, D
Ye, M
Nightingale, CH
Nicolau, DP
机构
[1] Hartford Hosp, Div Infect Dis, Ishikari, Hokkaido 06102, Japan
[2] Hartford Hosp, Dept Pharm Res, Ishikari, Hokkaido 06102, Japan
[3] Hartford Hosp, Res Off, Ishikari, Hokkaido 06102, Japan
关键词
D O I
10.1128/AAC.46.10.3185-3192.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Cethromycin (ABT-773), a new ketolide, possesses potent in vitro activity against Streptococcus pneumoniae. The objective of this study was to investigate the in vivo bactericidal activity of cethromycin against macrolide-susceptible and -resistant S. pneumoniae in a murine pneumonia model and to describe the pharmacodynamic (PD) profile of cethromycin. Eight (two macrolide susceptible, six macrolide resistant) clinical isolates of S. pneumoniae were investigated. Cyclophosphamide administration rendered ICR mice transiently neutropenic prior to intratracheal inoculation with 0.05 ml of an S. pneumoniae suspension containing 10(7) to 10(8) CFU/ml. Oral cethromycin was initiated 12 to 14 h postinoculation over a dosage range of 0.1 to 800 mg/kg of body weight/day. Lungs from seven to eight mice per treatment and control groups were collected at 0 and 24 h posttherapy to assess bacterial density. The cumulative mortality (n = 12 to 13) was assessed at 120 h (end of therapy) and at 192 h (3 days posttherapy). Recovery of pneumococci from the lungs of infected animals prior to the initiation of therapy ranged from 4.6 to 7.2 log(10) CFU. Growth in untreated control animals over a 24-h study period increased 0.3 to 2.7 log(10) CFU. Cethromycin demonstrated a substantial bactericidal effect, regardless of macrolide susceptibility. Correlation between changes in bacterial density (24 h) and survival over both 120 and 192 h were statistically significant. All three PD parameters demonstrated a significant correlation with changes in log(10) CFU/lung (Spearman's correlation coefficient, P < 0.001); however, the goodness of fit as assessed with the maximum effect (E(max)) model revealed that the maximum concentration of free drug in serum (C(max) (free))/MIC and the area under the free drug concentration-time curve (AUC(free))/MIC best explained the relationship between drug exposure and reductions in viable bacterial counts. These data reveal that an approximate cethromycin AUC(free)/MIC of 50 or C(max) (free)/MIC of 1 results in bacteriostatic effects, while higher values (twofold) maximize survival.
引用
收藏
页码:3185 / 3192
页数:8
相关论文
共 14 条
[1]   In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae:: Application to breakpoint determinations [J].
Andes, D ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2375-2379
[2]  
Bryskier A, 1997, INFEC DIS T, V21, P39
[3]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[4]  
CRAIG WA, 1998, J DRUG DEV S3, V1, P7
[5]   Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America:: 1997 results from the SENTRY antimicrobial surveillance program [J].
Doern, GV ;
Pfaller, MA ;
Kugler, K ;
Freeman, J ;
Jones, RN .
CLINICAL INFECTIOUS DISEASES, 1998, 27 (04) :764-770
[6]  
DUDLEY MN, 1982, NEW BETA LACTAM ANTI, P227
[7]  
HAMM TE, 1995, CONTEMP TOP LAB ANIM, V34, P69
[8]   Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem [J].
JolyGuillou, MC ;
Wolff, M ;
Pocidalo, JJ ;
Walker, F ;
Carbon, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :345-351
[9]  
National Committee for Clinical Laboratory Standards, 1993, METH DIL ANT SUSC TE
[10]  
Nicolau DP, 2001, INFECTION, V29, P11